摘要:
A process for the production of methionine which comprises (a) hydrolysing the methionine amide in the presence of a catalyst comprising titanium to produce ammonium methioninate, said catalyst having a porosity of from 5 to 1000 nm, a total pore volume of from 0.2 to 0.55 cm3/g and a surface area of from 30 to 150 m2/g, and (b) a second step of recuperating methionine from the ammonium methioninate salt by removing ammonia. Also claimed is an industrial process for the production of methionine incorporating the aforementioned hydrolysis.
摘要翻译:一种生产甲硫氨酸的方法,其包括(a)在包含钛的催化剂存在下水解甲硫氨酰胺以产生甲硫氨酸铵,所述催化剂的孔隙率为5-1000nm,总孔体积为0.2-0.55 cm 3 / g,表面积为30至150m 2 / g,和(b)通过除去氨将甲硫氨酸铵与甲硫氨酸铵回收的第二步骤 。 还要求的是用于生产掺入上述水解的甲硫氨酸的工业方法。
摘要:
The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR delta modulators to treat or inhibit the progression of, for example, dyslipidemia.
摘要:
Compounds of formula wherein the substituents are as defined in the specification which compounds are useful for inhibiting the activity of NO-synthase enzymes.
摘要:
The invention concerns more particularly dodecylthio-phenylacetanilide derivative complexes such as (S)-2′,3′,5′-trimethyl-4′-hydroxy-α-dodecylthio-phenylacetanilide or related derivatives thereof and cyclodextrins.
摘要:
The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.
摘要:
Specified phenylalanine derivatives and analogues thereof have an antagonistic activity to α 4 integrin. They are used as therapeutic agents for various diseases concerning α 4 integrin.
摘要:
The present invention provides illudin analogs of the general formula I: wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising compounds of formula I, intermediates and processes useful for preparing compounds of formula I, and methods comprising inhibiting tumor growth or treating cancer by administering one or more compounds of formula I.
摘要:
A carboxylic acid derivative of formula (I) wherein R1 is COOH, COOR6 etc.; A is alkylene etc.; R2 is alkyl, alkenyl, alkynyl etc.; B is carbocyclic ring or heterocyclic ring; R4 is alkyl, cycloalkyl etc.; R6 is carbocyclic ring or heterocyclic ring; or non-toxic salts thereof, a process for the preparation thereof and a pharmaceutical agent comprising the same as active ingredient. The compound of the formula (I) can bind to Prostaglandin E2 receptors, especially, EP3 receptor and/or EP4 receptor and show the antagonizing activity, and useful for the prevention and/or treatment of disease, for example, pain, allergy, Alzheimer's disease, cancer.
摘要翻译:式(I)的羧酸衍生物,其中R 1是COOH,COOR 6等; A是亚烷基等; R 2是烷基,烯基,炔基等; B是碳环或杂环; R 4是烷基,环烷基等; R 6是碳环或杂环; 或其无毒盐,其制备方法和包含其作为活性成分的药剂。 式(I)化合物可以结合前列腺素E2受体,特别是EP3受体和/或EP4受体,并显示拮抗活性,并且可用于预防和/或治疗疾病,例如疼痛,过敏,阿尔茨海默病 疾病,癌症。
摘要:
The present invention provides pharmaceutical compositions useful in treating hepatitis C infection. The present invention also provides methods of treating hepatitis C infection by administering to a mammal the pharmaceutical compositions of the present invention.